ELDN
NASDAQEledon Pharmaceuticals Inc.
News · 26 weeks35-60%
2025-12-142026-06-07
Mix2090d
- Other10(50%)
- SEC Filings8(40%)
- Earnings2(10%)
Latest news
25 items- PREledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D – All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline – No severe hypoglycemic episodes were reported post-transplant, compared with a history of recurrent severe hypoglycemic events prior to transplantation in all enrolled patients IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated tr
- PREledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific SessionsIRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana. Details of the oral presentation are as follows: Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet AllotransplantationSession: Immune Modulatory Strategies for Next-Gene
- PRNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesPre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi
- PREledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant CongressIRVINE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will present new clinical data from its tegoprubart program in patients undergoing kidney transplantation in an oral and a poster presentation at the American Transplant Congress (ATC) taking place in Boston, MA from June 20-24, 2026. Results will include updated data from the Phase 2 BESTOW clinical trial and new long-term data from the Phase 2 BESTOW extension study. Details on the presentations are below: Oral Presentation Title: Phase 2 BESTOW Trial: Evaluating Tegoprubart's Safety and Efficacy in Preventing Kidney Transplant Rejection Presenter: A
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
- SECSEC Form 10-Q filed by Eledon Pharmaceuticals Inc.10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECEledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PREledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights100% insulin independence achieved in 10 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study FDA Orphan Drug designation granted to tegoprubart for the prevention of allograft rejection in liver transplantation Cash, cash equivalents and short-term investments totaled $111.1 million as of March 31, 2026 IRVINE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter 2026 operating and financial results and provided recent business highlights. "In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including impo
- SECSEC Form EFFECT filed by Eledon Pharmaceuticals Inc.EFFECT - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECSEC Form S-3 filed by Eledon Pharmaceuticals Inc.S-3 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECSEC Form DEFA14A filed by Eledon Pharmaceuticals Inc.DEFA14A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECSEC Form DEF 14A filed by Eledon Pharmaceuticals Inc.DEF 14A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PRNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan
- PRNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (NASDAQ:ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy. The updated presentation outlines the integration of NewcelX's scalable stem-cell-derived islet replacement platform with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart, a targ
- PRWhy Smart Money Is Shifting From Clinical Data to Manufacturing LinesIssued on behalf of Avaí Bio, Inc.USANewsGroup.com News CommentaryVANCOUVER, BC, April 6, 2026 /CNW/ -- The global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has been proving itself for years. What most of these companies still lack is the production backbone to actually deliver at scale: GMP qualified facilities, traceable cell banks, and manufacturing processes that regulators will sign off on. The FDA accelerated the timeline in early 2026 by formalizing flexible manufacturing and quality control oversight for cell and gene therapies, clearing a path that had stalled the jump from clinical validati
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
- PREledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial ResultsReported updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Presented 24-month follow-up data from Phase 1b long-term extension study which continues to support the favorable safety and tolerability profile of tegoprubart Tegoprubart granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation IRVINE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2025 operating and financial results and reviewed recent business highlights. "Over the past year, Eledon
- SECSEC Form 10-K filed by Eledon Pharmaceuticals Inc.10-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- SECEledon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
- PREledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection or de novo donor-specific HLA antibodies - Tegoprubart continues to demonstrate a favorable safety and tolerability profile IRVINE, Calif, March 16, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced updated results from an investigator-initiated trial conducted at the University of Chicago Medicine Transplant Institute and presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChica
- PREledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver TransplantationIRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation. Tegoprubart has previously received orphan drug designation from the FDA for the prevention of allograft rejection in pancreatic islet cell transplantation and for the treatment of amyotrophic lateral sclerosis (ALS). "Clinical studies in kidney transplantation have demonstrated that tegoprubart has the potential to improve graft survival and function while reducing the side effects associated with calcin
- PRNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesCollaboration Integrates Stem-Cell-Derived Islets with Targeted Immune ModulationZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (NASDAQ:NCEL), a clinical-stage company advancing stem-cell-derived therapies for Type 1 Diabetes, today announced a collaborative research agreement with Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical-stage immunology company with a focus on transplant medicine. The collaboration is designed to advance combination strategies integrating NewcelX's lead program, NCEL-101, with Eledon's investigational anti-
- PREledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare ConferenceIRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the upcoming Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026, at 1:40 p.m. ET (10:40 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology co
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Eledon Pharmaceuticals Inc.SCHEDULE 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
- PREledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT). To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the m
ELDN FAQ
7 questionsWhat does Eledon Pharmaceuticals Inc. do?
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was...Where does ELDN stock trade?
Eledon Pharmaceuticals Inc. (ELDN) is listed on NASDAQ.What sector and industry is ELDN in?
Eledon Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eledon Pharmaceuticals Inc. go public?
Eledon Pharmaceuticals Inc. (ELDN) completed its IPO in 2014.What are analysts saying about ELDN?
Eledon Pharmaceuticals Inc. has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $900.00 price target on 2025-06-18. Recent price targets range from $900.00 to $2500.00.What companies are similar to ELDN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ELDN side-by-side with any of them on Quantisnow.How can I track ELDN on Quantisnow?
Quantisnow aggregates Eledon Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELDN to receive live email and push alerts on every new disclosure.